0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Radiological Case of the Month FREE

[+] Author Affiliations

Section Editor: Beverly P. Wood, MD

More Author Information
Arch Pediatr Adolesc Med. 2001;155(7):848. doi:10.1001/archpedi.155.7.847.
Text Size: A A A
Published online

DENOUEMENT AND DISCUSSION: CEREBRAL AIR EMBOLISM IN HEREDITARY HEMORRHAGIC TELANGIECTASIA (OSLER-WEBER-RENDU DISEASE)

Figure 1. Pulmonary arteriovenous malformation.

Figure 2. Pulmonary hemorrhage.

Figure 3. Initial computed tomography of the brain demonstrating diffuse pneumocephaly with edema and mass effect without hemorrhage.

Osler-Weber-Rendu disease (OWR), or hereditary hemorrhagic telangiectasia, is an autosomal dominant disorder involving vascular structures throughout the body. The incidence of OWR is estimated at 1 to 2 per 100 000.1 The classic triad consists of telangiectasias, epistaxis, and previous familial history. Because of variable penetrance, a family history of OWR may be absent. This patient's mother and grandfather had a history of recurrent gastrointestinal bleeding, and the mother required frequent blood transfusions. The underlying pathologic abnormality of OWR is a combination of insufficient smooth muscle contractile elements, endothelial cell junction defects, and perivascular connective tissue weakness.1 These defects give rise to telangiectasias, arteriovenous malformations (AVMs), and aneurysms. Two gene defects have been linked to OWR. The defect involves the endoglin gene located on chromosome 9, which is often associated with pulmonary and cerebral AVMs.2

A defect located on the ALK1 gene on chromosome 12 has also been reported.3 Epistaxis is often an initial presenting manifestation. Cutaneous telangiectasias may not manifest until the second or third decade of life. Aneurysms and AVMs may affect multiple organs. Lesions of the gastrointestinal tract manifest as painless bleeding.1 Fibrovascular infiltration of the liver can cause hepatomegaly, and left-to-right shunting through fistulas may cause high-output congestive heart failure.4

This patient's prior hemoptysis was associated with a pulmonary AVM; these are found in 5% to 15% of patients affected with OWR.4 Most often these fistulas remain stable or gradually expand over decades.1 Treatment for pulmonary AVMs or fistulas is surgical excision, embolization, or ligation, and is reserved for those fistulas or AVMs that are expanding or symptomatic. A cerebral air embolism can occur from a pulmonary AVM,5 leading rapidly to progressive cerebral edema, uncal herniation, and death. Other more common neurologic complications of OWR-associated AVMs include septic microemboli, producing an abscess or meningitis, and vascular malformations of the brain and spinal cord.4 Patients may develop headaches or transient ischemic attacks.

Although patients with OWR can have repeated episodes of hemorrhage, the lifespan is neither inevitably reduced nor is quality of life impaired.1 Treatment is supportive, including iron therapy for chronic anemia. Frequent transfusions, surgical resection, embolization, or irradiation may be necessary for repeated bleeding or life-threatening AVMs. The use of hormonal therapy (mostly oral estrogens) has been reported for severe cases of recurrent epistaxis and for recurrent gastrointestinal bleeding.6,7

Accepted for publication November 3, 1999.

Reprints: Toni M. Petrillo, MD, Children's Healthcare of Atlanta at Egleston, Division of Pediatric Critical Care, 1405 Clifton Rd NE, Atlanta, GA 30322 (e-mail: toni.petrillo@CHOA.org).

Perry  WH Clinical spectrum of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Am J Med. 1987;82989- 997
Link to Article
Shovlin  CL Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet. 1997;6168- 79
Link to Article
Johnson  DWBerg  JNBaldwin  MA  et al.  Mutations in activin receptor-like kinase gene in hereditary hemorrhagic telangiectasia type 2. Nat Genet. 1996;13189- 195
Link to Article
Guttmacher  AEMarchuk  DAWhite  RI  Jr Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333918- 924
Link to Article
Stanley  IMHunter  KR Neurological manifestations of hereditary hemorrhagic teleangiectasia. BMJ. 1970;3688
Link to Article
Custem  EV Estrogen-progesterone treatment of Osler-Weber-Rendu disease. J Clin Gatroenterol. 1988;10676- 679
Link to Article
Custem  EV Treatment of bleeding gastrointestinal vascular malformations with estrogen-progesterone. Lancet. 1990;335953- 955
Link to Article

Tables

References

Perry  WH Clinical spectrum of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Am J Med. 1987;82989- 997
Link to Article
Shovlin  CL Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet. 1997;6168- 79
Link to Article
Johnson  DWBerg  JNBaldwin  MA  et al.  Mutations in activin receptor-like kinase gene in hereditary hemorrhagic telangiectasia type 2. Nat Genet. 1996;13189- 195
Link to Article
Guttmacher  AEMarchuk  DAWhite  RI  Jr Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333918- 924
Link to Article
Stanley  IMHunter  KR Neurological manifestations of hereditary hemorrhagic teleangiectasia. BMJ. 1970;3688
Link to Article
Custem  EV Estrogen-progesterone treatment of Osler-Weber-Rendu disease. J Clin Gatroenterol. 1988;10676- 679
Link to Article
Custem  EV Treatment of bleeding gastrointestinal vascular malformations with estrogen-progesterone. Lancet. 1990;335953- 955
Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles